AlphAIAlphAI — Financial news for AI agents
rttnews.com$AMRX

Amneal Pharma Posts Wider Q3 Loss Despite 10% Revenue Growth; Raises FY26 Outlook

Amneal Pharma (AMRX) reported a wider Q3 loss of $21.69M, up from $2.37M YoY, despite 10% revenue growth to $862.68M. Adjusted EPS rose 53% to $0.26. The company raised FY26 revenue guidance to $3.15B-$3.25B and adjusted EBITDA to $800M-$815M. AMRX stock is down 1.17% in pre-market trading.

Original reporting
rttnews.com
Published Nov 3, 2026, 12:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMRX
Bullish
high confidence
Mentioned
$AMRX
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$AMRXBullishMed
01

Why it matters

The earnings miss and loss expansion may trigger a sell-off, though the raised revenue outlook offers a potential upside catalyst.

02

Market read

First report of Amneal's Q3 results and FY guidance, providing actionable data for traders.

03

What to watch

Acquisition-related share dilution and biosimilar pipeline progress could support future growth.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Amneal Pharma disclosed its Q3 2026 results, showing a 10% revenue increase but a wider net loss, and updated FY26 guidance.

Company-level read

Ticker impact

$AMRXBullishHigh confidence
Context

Amneal Pharma reported Q3 loss widening and raised FY26 guidance, providing fresh earnings data and outlook.

Expected impact

likely downward pressure as investors weigh wider loss against modest guidance lift

Evidence & confidence

New earnings release with fresh numbers and guidance change drives immediate market reaction.

Market effects

Sector

Generic pharma sector may see mixed sentiment as revenue growth offsets widening losses.

Regional

U.S. biotech stocks could face slight pullback amid earnings disappointment.

Global

Limited to U.S. listed biotech; no broader macro impact.

Counterpoint

What could challenge this read

Guidance raise may signal longer-term upside despite short-term loss.

Key entities

  • company
    Amneal Pharmaceuticals, Inc.

    U.S.-listed generic and specialty drug maker.

Read at source← All news

StoryAmneal Pharmaceuticals raises 2026 revenue and earnings guidance after Q3 2026 results

Also covered by

5 outlets

Related articles

$AMRXHighAI 8/10

Amneal Earnings Call Signals Strong Growth Ahead

Amneal Pharmaceuticals (AMRX) reported Q3 revenue of $863M, up 10% YoY, with adjusted EBITDA rising 30% to $207M and adjusted EPS increasing 53% to $0.26. The company raised its 2026 revenue outlook to $3.15B-$3.25B and adjusted EBITDA guidance to $800M-$815M. Growth was driven by specialty brands, the Kashiv acquisition, and biosimilar platforms, though management noted pressure from AvKARE and temporarily higher leverage.

tipranks.com
$AMRXMed

Piper Sandler reiterates Amneal stock rating on earnings beat

Piper Sandler maintained an Overweight rating and $21.00 price target for Amneal Pharmaceuticals (NYSE: AMRX) after its Q3 earnings beat estimates. Amneal reported $0.26 EPS on $862.7M revenue, raising 2026 revenue guidance to $3.15B-$3.25B. Shares are up 78% year-over-year, trading near a 52-week high. Piper Sandler expects steady EBITDA growth and improved leverage ratios.

investing.com
$AMRXMedAI 8/10

What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call

Amneal Pharmaceuticals (AMRX) reported Q3 revenue growth in affordable medicines (19% to $547M) and specialty products (20% to $150M), while AvKARE revenue declined 17% to $165M. Adjusted gross margin increased to 43.2%. The company launched lanreotide, targeting 30-40% market share, and expects significant biosimilar growth. Specialty brands like CREXONT and BREKIYA showed strong performance. Amneal plans manufacturing expansions and aims to reduce leverage below 3x EBITDA by 2028.

finance.yahoo.com